# Cytokinetics

**Type:** Funders  
**Canonical URL:** https://scholariq.org/funders/cytokinetics/

## Facts

| Field | Value |
| --- | --- |
| Country | US |
| Description | company in South San Francisco, United States |
| OpenAlex ID | https://openalex.org/F4320315432 |
| ROR ID | https://ror.org/03tx9ss94 |
| Works | 1,579 |

## Funder papers

- [Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction](https://scholariq.org/papers/angiotensin-neprilysin-inhibition-in-heart-failure-with-preserved-ejection/)
- [Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial](https://scholariq.org/papers/safety-and-tolerability-of-the-novel-non-steroidal-mineralocorticoid-receptor/)
- [Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction](https://scholariq.org/papers/efficacy-of-dapagliflozin-on-renal-function-and-outcomes-in-patients-with-heart/)
- [Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF](https://scholariq.org/papers/initial-decline-dip-in-estimated-glomerular-filtration-rate-after-initiation-of/)
- [Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease](https://scholariq.org/papers/efficacy-and-safety-of-spironolactone-in-patients-with-hfpef-and-chronic-kidney/)
- [Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD](https://scholariq.org/papers/correlates-and-consequences-of-an-acute-change-in-egfr-in-response-to-the-sglt2/)
- [Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial](https://scholariq.org/papers/vericiguat-in-patients-with-chronic-heart-failure-and-reduced-ejection-fraction/)
- [Finerenone, Serum Potassium, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction](https://scholariq.org/papers/finerenone-serum-potassium-and-clinical-outcomes-in-heart-failure-with-mildly/)
- [Costs of illness in amyotrophic lateral sclerosis (ALS): a cross-sectional survey in Germany](https://scholariq.org/papers/costs-of-illness-in-amyotrophic-lateral-sclerosis-als-a-cross-sectional-survey/)
- [Secondary analysis of the EMPACT-MI trial reveals cardiovascular–kidney efficacy and safety of empagliflozin after acute myocardial infarction](https://scholariq.org/papers/secondary-analysis-of-the-empact-mi-trial-reveals-cardiovascular-kidney-efficacy/)
- [A comparison of quality-adjusted life years in older adults after heart transplantation versus long-term mechanical support: Findings from the SUSTAIN-IT study](https://scholariq.org/papers/a-comparison-of-quality-adjusted-life-years-in-older-adults-after-heart/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.